NurExone Unveils Breakthrough in Facial Nerve Regeneration at ISEV 2025

NurExone Biologic ( (TSE:NRX) ) just unveiled an update.

NurExone Biologic Inc. announced a breakthrough in facial nerve regeneration with its lead candidate, ExoPTEN, at the 2025 International Society for Extracellular Vesicles Annual Meeting. The preclinical study demonstrated significant functional recovery in facial nerve injuries, potentially opening new therapeutic avenues for conditions like Bell’s palsy and Ramsay Hunt Syndrome. This advancement positions NurExone to enter a third multi-billion dollar market, enhancing its economic model by addressing multiple high-value indications with a single manufacturing process. The company’s ExoTherapy platform, which uses exosomes for precise delivery of therapies, is advancing towards clinical translation, supported by a granted U.S. patent and pending applications worldwide.

More about NurExone Biologic

NurExone Biologic Inc. is a biotechnology company listed on the TSX Venture Exchange, OTCQB, and Frankfurt, focusing on regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has shown strong preclinical potential in treating acute spinal cord and optic nerve injuries, targeting multi-billion-dollar markets. The company is advancing towards clinical trials in the U.S. and Europe and has established a U.S. subsidiary, Exo-Top Inc., to support its North American growth strategy.

YTD Price Performance: 9.84%

Average Trading Volume: 33,476

Technical Sentiment Signal: Sell

Current Market Cap: C$38.58M

For a thorough assessment of NRX stock, go to TipRanks’ Stock Analysis page.